ATE394122T1 - Hemmung des cd95 liganden/rezeptor-systems zur behandlung von neurologischen erkrankungen und verletzungen - Google Patents

Hemmung des cd95 liganden/rezeptor-systems zur behandlung von neurologischen erkrankungen und verletzungen

Info

Publication number
ATE394122T1
ATE394122T1 AT04709605T AT04709605T ATE394122T1 AT E394122 T1 ATE394122 T1 AT E394122T1 AT 04709605 T AT04709605 T AT 04709605T AT 04709605 T AT04709605 T AT 04709605T AT E394122 T1 ATE394122 T1 AT E394122T1
Authority
AT
Austria
Prior art keywords
treatment
injuries
ligand
inhibition
receptor system
Prior art date
Application number
AT04709605T
Other languages
English (en)
Inventor
Ana Martin-Villalba
Peter Krammer
Deana Demjen
Original Assignee
Deutsches Krebsforsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforsch filed Critical Deutsches Krebsforsch
Application granted granted Critical
Publication of ATE394122T1 publication Critical patent/ATE394122T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
AT04709605T 2003-02-14 2004-02-10 Hemmung des cd95 liganden/rezeptor-systems zur behandlung von neurologischen erkrankungen und verletzungen ATE394122T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03003426A EP1447093A1 (de) 2003-02-14 2003-02-14 Inhibition des CD95 Ligand/Rezeptorsystems zur Behandlung neurologischer Störungen und Verletzungen

Publications (1)

Publication Number Publication Date
ATE394122T1 true ATE394122T1 (de) 2008-05-15

Family

ID=32668981

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04709605T ATE394122T1 (de) 2003-02-14 2004-02-10 Hemmung des cd95 liganden/rezeptor-systems zur behandlung von neurologischen erkrankungen und verletzungen

Country Status (10)

Country Link
US (1) US7935339B2 (de)
EP (2) EP1447093A1 (de)
JP (1) JP4800920B2 (de)
AT (1) ATE394122T1 (de)
AU (1) AU2004212308C1 (de)
CA (1) CA2514794C (de)
DE (1) DE602004013540D1 (de)
DK (1) DK1592446T3 (de)
ES (1) ES2301966T3 (de)
WO (1) WO2004071528A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0719459A2 (pt) 2006-12-22 2014-02-04 Genentech Inc "métodos para inibir a ligação do receptor de morte 6 (dr6) à proteína precursora amilóide (app), para o tratamento, para identificação de uma molécula de interesse que inibe a ligação do dr6 à app, para diagnosticar um paciente com, antagonista dr6 isolado, composição farmacêutica, artigo manufaturado e kit"
US9309320B2 (en) 2006-12-28 2016-04-12 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Neutralization of CD95 activity blocks invasion of glioblastoma cells in vivo
EP2318441A2 (de) * 2008-07-14 2011-05-11 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Verwendung eines cd95-inhibitors zur behandlung von entzündlichen erkrankungen
MX2011005481A (es) 2008-11-25 2011-08-17 Biogen Idec Inc Uso de antagonistas de receptor de muerte 6 (drg6) y de p75 para promover la supervivencia de células del sistema nervioso.
CN102612374A (zh) 2009-11-12 2012-07-25 霍夫曼-拉罗奇有限公司 提升树突棘密度的方法
IL258844B2 (en) 2015-10-22 2024-03-01 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
CN111546719B (zh) * 2020-04-21 2022-07-01 中国船舶重工集团公司第七二五研究所 一种磁性宽频带电磁吸波超材料

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4447484C2 (de) * 1994-04-08 1997-07-17 Deutsches Krebsforsch Mittel zur Hemmung von Apoptose
JP3925663B2 (ja) 1995-06-30 2007-06-06 持田製薬株式会社 抗Ｆａｓリガンド抗体および該抗体を用いた測定法
EP1449539A2 (de) 1996-10-31 2004-08-25 Mochida Pharmaceutical Co., Ltd. Vorbeugende oder therapeutische Verwendung eines Fas-Antagonisten zur Inhibierung Fas-mediierten Apoptose
US6001962A (en) * 1996-11-15 1999-12-14 The Regents Of The University Of California Modified Fas ligands
ATE393222T1 (de) 1997-09-18 2008-05-15 Genentech Inc Dcr3 polypeptid, ein tnfr homolog
DE60036199T2 (de) * 1999-03-30 2008-05-21 Eli Lilly And Co., Indianapolis Proteaseresistente flint-analoge
KR100386399B1 (ko) * 1999-05-26 2003-06-02 이쿠오 토라따니 짧은 바지 및 수영복 등의 의류
DE19959049A1 (de) * 1999-12-07 2001-06-28 Deutsches Krebsforsch Kombination von Verbindungen, welche die biologischen Wirkungen von TNF-alpha und CD95L hemmen
US6689784B2 (en) * 2000-03-29 2004-02-10 Vertex Pharmaceuticals Incorporated Carbamate caspase inhibitors and uses thereof
US7115717B2 (en) * 2001-05-18 2006-10-03 Kirin Beer Kabushiki Kaisha Anti-TRAIL-R antibodies

Also Published As

Publication number Publication date
EP1592446B1 (de) 2008-05-07
DK1592446T3 (da) 2008-09-01
JP2006517559A (ja) 2006-07-27
ES2301966T3 (es) 2008-07-01
EP1592446A1 (de) 2005-11-09
JP4800920B2 (ja) 2011-10-26
US20060234968A1 (en) 2006-10-19
DE602004013540D1 (de) 2008-06-19
CA2514794C (en) 2013-05-28
AU2004212308A1 (en) 2004-08-26
EP1447093A1 (de) 2004-08-18
AU2004212308B2 (en) 2009-05-21
US7935339B2 (en) 2011-05-03
WO2004071528A1 (en) 2004-08-26
CA2514794A1 (en) 2004-08-26
AU2004212308C1 (en) 2009-10-29

Similar Documents

Publication Publication Date Title
ATE427759T1 (de) Behandlung von fettsucht und verbundenen erkrankungen
ATE445415T1 (de) Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung
ATE554756T1 (de) Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen
ATE440866T1 (de) Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten
DE60216139D1 (de) Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen
IL219857A0 (en) Mitotic kinesin inhibitors, pharmaceutical compositions comprising them, uses thereof in the manufacture of a medicament for the treatment of disease or disorder in a human or animal that can be treated by inhibiting mitosis
ATE286028T1 (de) Aminopyrazolderivate zur behandlung von übergewicht und anderen gesundheitsstörungen
DE602004008069D1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
ATE555803T1 (de) Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen
ATE415968T1 (de) 3,11b-cis-dihydrotetrabanezin zur behandlung von schizophrenie und anderen psychosen
TW200505904A (en) Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
ATE456955T1 (de) Verwendung von cyclodextrin zur behandlung und vorbeugung von entzündlichen bronchialerkrankungen
ATE422498T1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
DE50109156D1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
DE60008753D1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
ATE494890T1 (de) Alpha-aminoamid-derivate zur behandlung von suchtstörungen
ATE446754T1 (de) Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten
NO20054913D0 (no) Anvendelse av clustein for behandling og/eller forebyggelse av perifere nevrologiske lidelser
ATE394122T1 (de) Hemmung des cd95 liganden/rezeptor-systems zur behandlung von neurologischen erkrankungen und verletzungen
ATE359783T1 (de) Aroylpyrrolheteroeryl und methanole zur behandlung von störungen des zentralnervensystems
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
TW200735868A (en) Compositions and methods for treating CNS disorders
IS8540A (is) Notkun TWEAK stilla og tálma til að meðhöndla taugasjúkdóma
ATE494903T1 (de) Verwendung von slurp-1 zur behandlung von krankheiten, die durch störungen der acetylcholinerezeptoren ausgelöst werden

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1592446

Country of ref document: EP

REN Ceased due to non-payment of the annual fee